Compare ASML Holding NV (ASML) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASML Holding NV vs Summit Therapeutics Inc — how do they compare? ASML Holding NV trades at $1,816 (market cap $689.17B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: ASML Holding NV is far larger — about 57.1× Summit Therapeutics Inc's market cap, and ASML Holding NV pays a 0.5% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ASML | SMMT | |
|---|---|---|
Market Cap | $689.17B | $12.06B |
Sector | Technology | Health |
52-Week High | $1.99K | $26.98 |
52-Week Low | $725.85 | $12.55 |
Enterprise Value | $682.70B | $11.39B |
Dividend Yield | 0.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASML trades at $1,819.44, up 4.96% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with 2025 revenue of $32.67B and net income of $9.61B, though valuation ratios like a P/E of 61.28 are elevated. Recent earnings beat expectations in Q1 and Q2 2026, and analyst consensus is a Buy with a $2,390 price target. News highlights AI-driven demand for its semiconductor equipment.
Outlook is positive due to AI lithography demand and High-NA EUV expansion, but risks include high valuation sensitivity and geopolitical threats from Chinese self-sufficiency efforts. The stock offers growth potential with 31% upside to the consensus target, balanced by execution and competitive risks.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
